J.-L. Breton

TL;DR: The results confirm the efficacy of chemotherapy in brain metastases of NSCLC and suggest that the timing (early or delayed) of WBRT did not influence survival in patients with non-small-cell lung cancer with brain metastasis treated with concurrent chemotherapy.

TL;DR: There was no advantage in PFS with GD compared with CV; however, the CV regimen had higher rate of toxic events, mainly myelosuppression, and the herein, non-platinum-containing regimen could be considered as a rational alternative to the cisplatin-based doublet.

TL;DR: While both schedules of docetaxel administration in patients with pretreated NSCLC had a favourable safety profile, a significant lower rate of severe neutropenia was observed in the weekly arm, and both regimens had similar efficacy.

TL;DR: Although severe events were uncommon, nausea/vomiting and diarrhoea were frequent and primary prophylaxis with antiemetics should be recommended, the safety profile of oral vinorelbine at 60 mg/m2/week for the first three courses with escalation to 80 mg/ m2 is qualitatively comparable to that of i.v. vinorubine at standard doses.

TL;DR: The overall results suggest that patients even older than 70 years may benefit from full treatment, and consideration should be given to offering active treatment to most patients with SCLC, regardless of age but with special attention paid to comorbidities.